跳转至内容
Merck
所有图片(1)

文件

C0691000

头孢曲松 二钠盐 半(七水合物)

European Pharmacopoeia (EP) Reference Standard

别名:

Ceftriaxone disodium salt hemi(heptahydrate)

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C18H16N8Na2O7S3 · 3.5H2O
CAS号:
104376-79-6
分子量:
661.60
EC號碼:
277-930-0
MDL號碼:
MFCD01750405
分類程式碼代碼:
41116107
PubChem物質ID:
329774815
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

ceftriaxone

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

InChI 密鑰

PMRZKYOXTPBIQF-MAODNAKNSA-J

正在寻找类似产品? 访问 产品对比指南

相关类别

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Ceftriaxone sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark
GHS08,GHS07

訊號詞

Danger

危險分類

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 1

閃點（°F）

Not applicable

閃點（°C）

Not applicable

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Zhihui Luo et al.
Journal of biomedical nanotechnology, 9(1), 69-76 (2013-05-01)
In this paper, the selectively enhanced antibacterial effects of ZnO nanorods with several kinds of conventional medical antibiotics are investigated. Compares to gentamicin, clarithromycin and ofloxacin, ZnO nanorods could obviously achieve synergistic antibacterial effects with ceftriaxone against Escherichia coli (E.
Filippo Lagi et al.
Journal of travel medicine, 20(2), 128-130 (2013-03-08)
We present the case of two Australian tourists aged 25 and 26  years who, after immersion in a canal in Venice, developed severe leptospirosis. After a 1-week history of fever, headache, myalgia, and vomiting they developed jaundice and renal failure.
Catherine A Ison et al.
The Lancet. Infectious diseases, 13(9), 762-768 (2013-06-15)
Effective treatment of gonorrhoea is fundamental to public health control; however, the ability of Neisseria gonorrhoeae to successively develop resistance to different treatments has hampered control efforts. The extended-spectrum cephalosporins--cefixime and ceftriaxone--have been recommended in the UK for treatment of
Phillip J Read et al.
Sexual health, 10(5), 460-462 (2013-09-14)
Emerging antimicrobial resistance within Neisseria gonorrhoeae (NG) is a significant global public health threat. Detection and investigation of treatment failures is a crucial component of the World Health Organisation's response to this challenge. We report the cases of two homosexual
N Goire et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 18(14), 20444-20444 (2013-04-19)
Emergence and spread of Neisseria gonorrhoeae resistant to extended spectrum cephalosporins is a major problem threatening treatment of gonorrhoea and is further highlighted by the recent report of a second ceftriaxone-resistant N. gonorrhoeae strain (F89) in Europe, initially observed in
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门